Enhancing the anti-tumour activity of (177)Lu-DOTA-octreotate radionuclide therapy in somatostatin receptor-2 expressing tumour models by targeting PARP

Peptide receptor radionuclide therapy (PRRT) is an important treatment option for patients with somatostatin receptor-2 (SSTR2)-expressing neuroendocrine tumour (NET) though tumour regression occurs in only a minority of patients. Therefore, novel PRRT regimens with improved therapeutic activity are...

Descripción completa

Detalles Bibliográficos
Autores principales: Cullinane, Carleen, Waldeck, Kelly, Kirby, Laura, Rogers, Buck E., Eu, Peter, Tothill, Richard W., Hicks, Rodney J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7311440/
https://www.ncbi.nlm.nih.gov/pubmed/32576907
http://dx.doi.org/10.1038/s41598-020-67199-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7311440/
https://www.ncbi.nlm.nih.gov/pubmed/32576907
http://dx.doi.org/10.1038/s41598-020-67199-9

Ejemplares similares